Companies › Corcept Therapeutics
4 active drug programs in 9 registered trials: 6 Phase 2, 2 Phase 1, 1 Phase 3; Oncology, Neurology, Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| relacorilant Glucocorticoid receptor antagonist | NR3C1 | Phase 3 | Ovarian Neoplasm; Cushing Syndrome; Ovarian Cancer; Adenocarcinoma … | Dec 2026 |
| Dazucorilant (CORT113176) Glucocorticoid receptor antagonist | NR3C1 | Phase 2 | Amyotrophic Lateral Sclerosis | Nov 2027 |
| Miricorilant Glucocorticoid receptor modulator | NR3C1 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | – |
| Nenocorilant Glucocorticoid receptor antagonist | NR3C1 | Phase 1 | Neoplasms | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06108219 | Miricorilant | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | Gastroenterology | Feb 2026 |
| NCT07553663 | Miricorilant | Phase 1 | Nonalcoholic Steatohepatitis (NASH) | Gastroenterology | Sep 2026 |
| NCT05257408 | relacorilant | Phase 3 | Ovarian Neoplasm | Oncology | Dec 2026 |
| NCT03604198 | relacorilant | Phase 2 | Cushing Syndrome | Oncology | Dec 2026 |
| NCT06906341 | relacorilant | Phase 2 | Ovarian Cancer | Oncology | Dec 2026 |
| NCT07276373 | Nenocorilant | Phase 1 | Neoplasms | Oncology | Jan 2027 |
| NCT07259317 | relacorilant | Phase 2 | Adenocarcinoma | Oncology | Sep 2027 |
| NCT05726292 | relacorilant | Phase 2 | Prostate Cancer | Oncology | Oct 2027 |
| NCT05407324 | Dazucorilant (CORT113176) | Phase 2 | Amyotrophic Lateral Sclerosis | Neurology | Nov 2027 |
Cash and short-term investments of $371m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Jazz Pharmaceuticals Oticara Australia Nurix Therapeutics Exelixis Compass Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.